Strategic change in cystic fibrosis market
Sionna Treatment has ensured the initial public share of no nucleotide-binding proculator service (CFTR). Sionna's novel mechanisms are different from CF market leaders, vertex pharma, with CFTRion's CFTRion. With vertex dominating cf marketing with Trikafta and other treatments, the way…

